| Claim/function | Evidence type/model | Key quantitative/statistical detail | Primary source (first author year, journal) | URL/DOI |
|---|---|---|---|---|
| FBXO33 acts as an E3 ligase/substrate receptor that binds wild-type p53 and promotes its polyubiquitination and proteasomal degradation, driving EMT/metastatic traits in gallbladder cancer | Human gallbladder cancer study; co-IP, ubiquitination assays, CHX chase, MG132 rescue, domain mapping, xenografts, clinical specimens | 82 paraffin-embedded tumor specimens analyzed; 11 paired cases showed FBXO33 higher in tumor while p53 was higher in adjacent tissue; p53 half-life was longer after sh-FBXO33 and shorter after Flag-FBXO33; binding mapped to p53 aa100-293 and FBXO33 aa111-555; ubiquitination at p53 K291/K292; knockdown reduced migration/EMT and tumor growth (pqac-00000001, pqac-00000002, pqac-00000003, pqac-00000004) | Wu 2025, *Cell Death & Disease* | https://doi.org/10.1038/s41419-025-07372-y |
| FBXO33 suppresses stem cell-like properties and metastasis in NSCLC by promoting ubiquitination and degradation of MYC | Human NSCLC study; title/abstract-level evidence from peer-reviewed primary paper | Paper reports FBXO33 is low in NSCLC and inversely correlated with overall survival; overexpression promoted MYC ubiquitination/degradation and suppressed proliferation, migration, invasion, and stemness, but detailed fold-changes/HRs were not available in retrieved evidence (pqac-00000006, pqac-00000004) | Wei 2024, *Frontiers in Bioscience* | https://doi.org/10.31083/j.fbl2908296 |
| FBXO33 is a Cul1-based F-box ligase component that modulates ubiquitination, solubility, and aggregation of expanded ATXN3/polyQ proteins | Human SK-N-MC cells plus Drosophila genetic modifier work; co-IP, overexpression, ubiquitination assays, filter retardation, inhibitor studies, localization | FBXO33 overexpression increased SDS-soluble SCA3tr-Q78 and reduced filter-retardation-detected aggregates (n=3); selectively co-immunoprecipitated with expanded Q78 but not Q27; effect was blocked by proteasome inhibitor lactacystin, not chloroquine; Cul1 and FBXO33 localized to both nucleus and cytoplasm; co-expression reduced fraction of cells with polyQ aggregates (pqac-00000007, pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000011) | Chen 2019, *Journal of Neurochemistry* | https://doi.org/10.1111/jnc.14669 |
| FBXO33 interacts with YBX1 and contributes to YBX1 ubiquitination-dependent degradation; sciadopitysin stabilizes YBX1 partly by disrupting the FBXO33-YBX1 axis | Human/mouse BMSC aging study; co-IP with deletion mapping, CHX chase, ubiquitination assays with MG132, pharmacologic stabilization | YBX1 regions aa42-53 and aa128-322 were required for FBXO33 binding; sciadopitysin slowed YBX1 degradation, decreased YBX1 ubiquitination, lowered FBXO33 protein, and reduced FBXO33-YBX1 co-IP signal; in vivo treatment group n=8 showed increased BV/TV, Tb.Th, Tb.N, osteoblast numbers, MAR, and BFR, with fewer adipocytes and no osteoclast change (pqac-00000012, pqac-00000013, pqac-00000014) | Xiao 2023, *The EMBO Journal* | https://doi.org/10.15252/embj.2022111762 |
| FBXO33 is a negative regulator of cardiomyocyte hypertrophy in a functional screen | siRNA screen in neonatal rat cardiomyocytes with automated microscopy and 3H-isoleucine incorporation | Fbxo33 knockdown increased mean cell size to 1.31 ± 0.04 under PE treatment (p < 0.001) and increased 3H-isoleucine incorporation to 1.58 ± 0.06 (p < 0.001), indicating enhanced hypertrophic growth when Fbxo33 is depleted (pqac-00000005) | Fischer 2023, *Frontiers in Physiology* | https://doi.org/10.3389/fphys.2023.1134339 |
| Human genetics/association resources link FBXO33 to several traits and diseases, but these are association-level signals rather than mechanistic functional proof | Open Targets integrated disease-target evidence | Open Targets reported evidence sizes of 5 for insomnia, smoking initiation, disease of peritoneum, abnormality of the gastrointestinal tract, and glomerulonephritis; association scores included ~0.260 for insomnia, ~0.258 for smoking initiation, ~0.235 for disease of peritoneum/GI abnormality, and ~0.283 for glomerulonephritis (pqac-00000000) | Open Targets Platform, accessed via tool context | https://platform.opentargets.org/target/ENSG00000165355 |


*Table: This table summarizes the main experimentally supported functions and disease links for human FBXO33, emphasizing direct substrate/interactor evidence, model systems, and quantitative findings. It is useful for distinguishing strong mechanistic evidence from broader association-level annotations.*